Crossmark

Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study

Crossref DOI link: https://doi.org/10.1007/s00277-024-06017-y

Published Online: 2024-10-04

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wery, Alexandre-Raphael

Salaroli, Adriano

Andreozzi, Fabio

Paesmans, Marianne

Dewispelaere, Laurent

Heimann, Pierre

Wittnebel, Sebastian

Lewalle, Philippe
License Information

Text and Data Mining valid from 2024-10-04

Version of Record valid from 2024-10-04
More Information

Article History

Received: 28 June 2024

Accepted: 17 September 2024

First Online: 4 October 2024

Declarations

:

: The Jules Bordet Institute ethics committee approved this study (reference CE3167). All medical data were pseudonymized to ensure patient confidentiality.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below